Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Morie A. Gertz, Rafat Abonour, Sarah N. Gibbs, Muriel Finkel, Heather Landau, Suzanne Lentzsch, Grace Lin, Anuj Mahindra, Tiffany P. Quock, Cara A. Rosenbaum, Michael Rosenzweig, Surbhi Sidana, Sascha A. Tuchman, Ronald Witteles, Irina Yermilov, Michael S. Broder

Blood (2022) 140 (Supplement 1): 13129–13131.

https://doi.org/10.1182/blood-2022-156832

Published: 2022

Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Blood (2022) 140 (Supplement 1): 1830–1832.

https://doi.org/10.1182/blood-2022-168930

Published: 2022

Journal Articles

Young Adults with Multiple Myeloma Have Distinct Clinical and Molecular Characteristics Compared to Older Patients

Mateo Mejia Saldarriaga, Aubrie Sowa, David S Jayabalan, Cara A. Rosenbaum, Roger Pearse, Jorge Monge, Ruben Niesvizky, Mark Bustoros

Blood (2022) 140 (Supplement 1): 9951–9952.

https://doi.org/10.1182/blood-2022-170413

Published: 2022

Journal Articles

Clinical and Genomics Characteristics of Multiple Myeloma with Extramedullary Disease in the Mmrf Registry

Mateo Mejia Saldarriaga, David S Jayabalan, Aubrie Sowa, Jorge Monge, Cara A. Rosenbaum, Roger Pearse, Ruben Niesvizky, Sanjay Patel, Mark Bustoros

Blood (2022) 140 (Supplement 1): 4238–4239.

https://doi.org/10.1182/blood-2022-157191

Published: 2022

Journal Articles

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2742.

https://doi.org/10.1182/blood-2021-148385

Published: 2021

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Shaji K. Kumar, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Betsy Laplant, MS, Binod Dhakal, MS, Melissa Alsina, MD, Rafat Abonour, MD, Cara A. Rosenbaum, MD, William I Bensinger, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD PhD, Erica Kim, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142584

Published: 2020

Journal Articles

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Danny Luan, MPH, Paul J Christos, Dr.P.H., M.S., Michael Ancharski, MLS(ASCP), Danielle Guarneri, BS, CCRP, Roger Pearse, MD PhD, Adriana C Rossi, MD MSc, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Adrienne A. Phillips, MD MPH, Jingmei Hsu, MD, Ljiljana V. Vasovic, MD, Yen-Michael S. Hsu, MD PhD, Koen van Besien, MD PhD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140811

Published: 2020

Journal Articles

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Cara A. Rosenbaum, MD, Danny Luan, BS, MPH, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Koen Van Besien, MD PhD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 2026.

https://doi.org/10.1182/blood-2019-127710

Published: 2019

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Larysa Sanchez, MD, Heather J Landau, MD, Cara A. Rosenbaum, MD, Alex Abrahams, Cindy Chin, Brielle Liotta, BS, Natalie Agudo, RN, Sheetal Ramnath, Elizabeth Hoover, BS, Hafsa Rahman, Umut Ozbek, PhD, Oscar B Lahoud, MD, Hani Hassoun, MD, Keren Osman, MD

Blood (2019) 134 (Supplement_1): 3128.

https://doi.org/10.1182/blood-2019-126023

Published: 2019

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Todd Zimmerman, MD, Noopur S. Raje, Ravi Vij, Donna Reece, MD, Jesus G. Berdeja, MD, Leonor A Stephens, PhD, Kathryn McDonnell, Cara A. Rosenbaum, MD, Jagoda Jasielec, MD, Paul G Richardson, MD, Sandeep Gurbuxani, Jennifer Nam, Erica Severson, Brittany D. Wolfe, MMS, PA-C, Shaun Rosebeck, PhD, Andrew Stefka, Dominik Dytfeld, MD PhD, Kent Griffith, PhD, Andrzej Jakubowiak, MDPhD

Blood (2016) 128 (22): 675.

https://doi.org/10.1182/blood.V128.22.675.675

Published: 2016

Journal Articles

Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MDPhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Erica Severson, Leonor A Stephens, PhD, Kathryn McDonnell, Shaun Rosebeck, PhD, Todd Zimmerman, MD, Theodore Karrison, PhD, Jeffrey Zonder, MD

Blood (2016) 128 (22): 973.

https://doi.org/10.1182/blood.V128.22.973.973

Published: 2016

Journal Articles

Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)

Aliyah R Sohani, MD, Brandy Pitcher, MS, Amy Chadburn, MD, Jonathan W. Said, MD, Peter Martin, MD, Myron S. Czuczman, MD, Nancy L Bartlett, MD, Cara A. Rosenbaum, MD, John P. Leonard, MD, Bruce D. Cheson, MD, Eric D. Hsi, MD

Blood (2015) 126 (23): 334.

https://doi.org/10.1182/blood.V126.23.334.334

Published: 2015

Journal Articles

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Cara A. Rosenbaum, MD, Jeffrey A Zonder, MD, Craig E. Cole, MD, Ajai Chari, MD, Jennifer Nam, Leonor A Stephens, PhD, Kathryn McDonnell, Rebecca Uribe, Shaun Rosebeck, PhD, Tami Rashal, MD, Hagop Youssoufian, MD, Sarah Henry, Sharon Shacham, Michael Kauffman, MD PhD, Todd Zimmerman, MD, Theodore Karrison, PhD

Blood (2015) 126 (23): 4223.

https://doi.org/10.1182/blood.V126.23.4223.4223

Published: 2015

Journal Articles

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Cara A. Rosenbaum, MD, Brandelyn Pitcher, MS, Nancy L Bartlett, MD, Sonali M. Smith, MD, Jane Jijun Liu, MD, Eric D. Hsi, MD, Sin-Ho Jung, PhD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 2741.

https://doi.org/10.1182/blood.V126.23.2741.2741

Published: 2015

Journal Articles

Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study

Cara A. Rosenbaum, MD, Vishal Kukreti, MD, Jeffrey Zonder, MD, Daniel Lebovic, MD, Todd Zimmerman, MD, Jesus G. Berdeja, MD, Kathryn McDonnell, BS, Jessica Waite-Marin, MS, PA-C, Kent A. Griffith, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2109.

https://doi.org/10.1182/blood.V124.21.2109.2109

Published: 2014

Journal Articles

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Jonathan L. Kaufman, MD, Todd Zimmerman, MD, Cara A Rosenbaum, MD, Ajay K. Nooka, MD MPH, Leonard T Heffner, MD, R. Donald Harvey, PharmD, Charise Gleason, MSN, ANP-BC, AOCNP, Colleen Lewis, MSN, ANP-BC, AOCNP, Cathy Sharp, RN, MN, OCN, Kenisha W Barron, B.S, CCRC, Sagar Lonial, MD

Blood (2014) 124 (21): 32.

https://doi.org/10.1182/blood.V124.21.32.32

Published: 2014

NARROW

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Young Adults with Multiple Myeloma Have Distinct Clinical and Molecular Characteristics Compared to Older Patients

Clinical and Genomics Characteristics of Multiple Myeloma with Extramedullary Disease in the Mmrf Registry

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)

Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study

Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only